Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Anavex Life Sciences (AVXL) Stock Price & Analysis
1,296 Followers
AVXL Stock Chart & Stats
Day’s Range$3.69 - $3.91
52-Week Range― - ―
Previous Close$3.68
Volume886.70K
Average Volume (3M)N/A
Market Cap
$307.51M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.50Price Target Upside767.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Anavex Life Sciences News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressPipeline advances with developments in various programs, including the initiation of a Marketing Authorization Application for blarcamesine in Alzheimer's disease.
Financial HealthAnavex ended the fiscal quarter with strong financials, having significant cash reserves, indicating resources to fund operations for the foreseeable future.
Regulatory MilestonesAnavex has received positive feedback from regulators regarding the submission of an application for approval of blarcamesine in Europe to treat Alzheimer's disease.
Bears Say
Clinical TrialsRisk of clinical trial failure for blarcamesine could significantly impact the stock as successful trials are crucial for drug approval and market entry.
Drug Approval And LaunchFailure to obtain approval for blarcamesine across its target indications poses a substantial threat to the stock, hindering its prospects for commercial success.
Financial RiskPotential long-term dilution risk may affect shareholder value if the company seeks additional capital to fund its operations before blarcamesine becomes profitable.
---
Ownership Overview
7.76% Insiders
7.82% Mutual Funds
17.95% Other Institutional Investors
66.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Currently, no data Available
What is Anavex Life Sciences’s market cap?
Currently, no data Available
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is May 09, 2024 which is in 15 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Feb 07, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.035.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -$0.11.
How many shares outstanding does Anavex Life Sciences have?
Currently, no data Available
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went down -3.454%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Among the largest hedge funds holding Anavex Life Sciences’s share is Sheaff Brock Investment Advisors LLC. It holds Anavex Life Sciences’s shares valued at 347K.
---
Anavex Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.50 (767.82% Upside)
$32.50 (767.82% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 34.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $375.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.17%
12-Months-Change
Fundamentals
Return on Equity
-31.89%
Trailing 12-Months
Asset Growth
-0.20%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
---
AVXL Earnings Call
Q1 2024
0:00 / 0:00
---
AVXL Stock 12 Months Forecast
Average Price Target
$32.50
▲(767.82% Upside)
Technical Analysis
Best Analysts Covering AVXL
1 Year
1 Year Success Rate
1/21 ratings generated profit
1 Year Average Return
-38.42%
reiterated a buy rating 3 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 4.76% of your transactions generating a profit, with an average return of -38.42% per trade.
---